ClinicalTrials.gg
CompletedNCT03444883Updated Jan 5, 2021

Phase III Study to Evaluate Safety and Efficacy of Ilaprazole in Patients With NERD

A Phase 3 interventional study of Ilaprazole in Non-erosive Reflux Disease, sponsored by Il-Yang Pharm. Co., Ltd.. Completed at 11 sites in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-01-05.

Sponsored by Il-Yang Pharm. Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
277
Allocation
Randomized
Ages
19 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of Ilaprazole 20 mg in patients with non-erosive reflux disease. This study intends to demonstrate the clinical superiority of Ilaprazole 20 mg to placebo administered once daily for 4 weeks.

Read the detailed description

This study is multicenter, randomized, parallel, double blind, placebo-controlled phase III study

02

Conditions studied

  • Non-erosive Reflux Disease

Keywords

  • NERD
  • PPI
  • Ilaprazole
03

In context

Non-Erosive Reflux Disease

46 studies on the registry are indexed under Non-Erosive Reflux Disease; 7 are open to participants now.

This study's enrollment of 277 is above the median of 170 across 33 interventional studies indexed under Non-Erosive Reflux Disease.

Browse Non-Erosive Reflux Disease studies →

Lead sponsor

Il-Yang Pharm. Co., Ltd. is the lead sponsor of 34 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged ≥ 19 years and ≤ 80 years
  2. Diagnosed with non-erosive reflux disease meeting all of the following criteria:

    2-1) At least either heartburn or acid regurgitation has persisted for at least past 3 months before screening 2-2) Have experienced at least either heartburn or acid regurgitation of moderate or higher intensity on at least 2 days of 7 days prior to initiation of the product 2-3) Esophageal mucosal breaks by LA Classification are not observed on upper gastrointestinal endoscopy at screening

  3. Voluntarily provide written to participate in this study

Exclusion criteria

Exclusion Criteria:

  1. Esophageal stenosis, ulcerative stenosis, esophagogastric varices or Barrett esophagus confirmed by past upper gastrointestinal endoscopy within 1 year prior to screening
  2. Active peptic ulcer or gastrointestinal bleeding confirmed by past upper gastrointestinal endoscopy at screening or within 4 weeks prior to screening
  3. Abnormal value on laboratory test at screening:

    3-1) Total , Creatinine > (ULN) x 1.5 3-2) Alkaline Phosphatase, BUN > ULN x 2

  4. abnormal findings on (major arrhythmia, multifocal PVC, second-degree or higher AV block, etc.) within 3 months prior to screening
  5. Have taken H2 receptor antagonists (H2RA), prostaglandin preparations, mucosal protective drugs, prokinetics, etc. within 2 weeks prior to initiation of the product administration, or has taken PPIs within 4 weeks prior to initiation of the investigational product administration
  6. Expected to continuously take nonsteroidal antiinflammatory drugs (NSAIDs) including aspirin or preparations during the study
  7. Surgical or medical condition that may significantly influence the absorption, distribution, metabolism or excretion of drug, including but not limited to: history of major gastrointestinal surgery such as gastrectomy, gastroenterostomy, colectomy, gastric bypass, gastric ligation or gastric banding; presence or history of active inflammatory bowel disease within 12 months prior to screening; has undergone critical surgery that may influence gastric acid secretion with exception of surgeries such as appendectomy, cholecystectomy, and hysterectomy
  8. Zollinger-Ellison syndrome; past history of alcoholism or drug abuse
  9. Past history of allergic symptoms (rash, fever, pruritus, etc.) or to any ingredient of the Investigational product
  10. Past history of treated or untreated , with or without local recurrence or , within 5 years prior to screening (with exception of local basal cell carcinoma of skin)
  11. Pregnant or nursing women
  12. Women of who do not use proper during the study
  13. Active liver disease; or AST > ULN x 2 at screening; or history of hepatic encephalopathy, esophageal varix, or portacaval shunt
  14. Receiving renal dialysis or history of kidney transplantation or presence of severe renal impairment (stage 4 or 5 chronic renal disease)
  15. Participated in another clinical study and took an investigational product within 3 months prior to screening
  16. Considered by the investigator to be ineligible to participate in this study for other reasons
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
277 participants (actual)

Study arms

  • Active comparator
    Treatment Group

    10mg Ilaprazole x 2 tablets

    Drug: Ilaprazole

  • Placebo comparator
    Control Group

    10mg placebo of Ilaprazole x 2 tablets

    Drug: Ilaprazole

Interventions

  • 10mgx2 tablet once daily for weeks

    Also known as: IY81149

06

What researchers measure

Primary outcomes

  1. Rate of loss of esophagitis symptom at 4 weeks of treatment vs pre-dose

    Percentage of subjects who were assessed as having 'lost' the frequency and intensity of typical esophagitis symptoms by RDQ assessment at 4 weeks of treatment

    Time frame: 4 weeks(28 days)

Secondary outcomes

  1. Chang in esophagitis symptom score at 4 weeks of treatment vs pre-dose

    The mean scores for esophagitis symptom (heartburn and/or acid regurgitation) frequency and intensity assessed with RDQ (Questions a, b/c, d) and the change in mean score across both domains.

    Time frame: 4 weeks(28 days)

  2. Change in PAGI-QoL score at 4 weeks of treatment vs pre-dose

    The change in mean score for quality of life assessed with PAGI-QoL

    Time frame: 4 weeks(28 days)

  3. Change in esophagitis symptom score according to the maximum number of rescue medication doses per day

    The mean scores for esophagitis symptom (heartburn and/or acid regurgitation) frequency and intensity assessed with RDQ (Questions a, b/c, d) at 4 weeks of treatment versus pre-dose according to the maximum number of rescue medication doses per day and the change in mean score across both domains.

    Time frame: 4 weeks(28 days)

07

Study locations

11 sites
  • Seoul National University Bundang Hospital
    Seongnam-si, Bundang-gu, Korea, Republic of
  • Inje University Busan Paik Hospital
    Busan, Busanjin-gu, Korea, Republic of
  • Seoul Metropolitan Government Seoul National University Boramae Medical Center
    Seoul, Dongjak-gu, Korea, Republic of
  • Chonbuk National University Hospital
    Jeonju, Jeonju-si, Korea, Republic of
  • Kangbuk Samsung Hospital, Sungkyunkwan University
    Seoul, Jongno-gu, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Jongno-gu, Korea, Republic of
  • Inje University Seoul Paik Hospital
    Seoul, Jung-gu, Korea, Republic of
  • Severance Hospital Yonsei University Health System
    Seoul, Seodaemun-gu, Korea, Republic of
  • Asan Medical Center
    Seoul, Songpa-gu, Korea, Republic of
  • Soon Chun Hyang University Hospital, Buchon
    Bucheon, Wonmi-gu, Korea, Republic of
  • Ewha Womans University Mokdong Hospital
    Seoul, Yangcheon-gu, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared to other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Feb 2020, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2018
First posted
Feb 23, 2018
StartActual
Oct 31, 2018
Primary completionActual
Feb 25, 2020
CompletionActual
Feb 25, 2020
Last update
Jan 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03444883
Responsible party
Sponsor
First posted
Feb 23, 2018
Start date
Oct 31, 2018
Primary completion
Feb 25, 2020
Completion
Feb 25, 2020
Last update
Jan 5, 2021

Study contacts

DongHo Lee, MD.PhD
principal investigator · Seoul National University Bundang Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ilaprazole

Start the discussion